Matching articles for "Alrex"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • January 22, 2024; (Issue 1694)
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in...
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear
evaporation caused by meibomian gland dysfunction.
An ophthalmic solution with a similar name, Meibo
Tears (Vista), which contains 0.6% propylene glycol, is
available over the counter for dry eye relief.
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • December 13, 2021; (Issue 1639)
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the...
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the US
for this indication. An oral formulation of varenicline
(Chantix, and generics) has been available for years
for smoking cessation.
Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021; (Issue 1624)
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved for
this indication. Other formulations of loteprednol are
approved for treatment of steroid-responsive ocular
inflammatory conditions, inflammation after ocular
surgery, and seasonal allergic conjunctivitis.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • February 1, 2010; (Issue 90)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83) are prevalent worldwide, especially in...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83) are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control these allergic diseases, patients should be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms. Allergen-specific immunotherapy may be useful for treatment of allergic rhinitis and allergic conjunctivitis, and in preventing severe insect venom-triggered reactions.